Blood levels of toxic and essential metals in motor neuron disease

NeuroToxicology

Volumn 22, Issue 3, 2001, Pages 401-410

  Pamphlett, Roger ^a   McQuilty, Robert ^b   Zarkos, Konstantinos ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Amyotrophic lateral sclerosis; Blood; Essential metal; Heavy metal; Motor neuron disease

Indexed keywords

CADMIUM; HEAVY METAL; LEAD;

ABSORPTION SPECTROPHOTOMETRY; ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC APPROACH ROUTE; ERYTHROCYTE FRAGILITY; FEMALE; HEMOLYSIS; HUMAN; MALE; MOTOR NEURON DISEASE; OSMOSIS; PATHOGENESIS; PRIORITY JOURNAL;

ADULT; AGED; CADMIUM; HEAVY METAL POISONING, NERVOUS SYSTEM; HUMANS; MALE; METALS, HEAVY; MIDDLE AGED; MOTOR NEURON DISEASE; STATISTICS, NONPARAMETRIC;

EID: 0034951763     PISSN: 0161813X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-813X(01)00029-8     Document Type: Article

References (41)

1. Retrograde axonal transport of cadmium in the rat hypoglossal nerve
2. Retrograde axonal transport of mercury
3. Retrograde axonal transport of metals
4. Variation in blood concentrations of cadmium and lead in the elderly
5. Adult onset motor neuron disease: Worldwide mortality, incidence and distribution since 1950
6. Risk factors for motor neuron disease: A case-control study based on patients from the Scottish Motor Neuron Disease Register
7. Mercury
8. Cytotoxic activity in the plasma of amyotrophic lateral sclerosis (ALS) patients against normal erythrocytes. Quantitative determinations
9. Immunoglobulin-mediated cytotoxic effect of ALS-plasma towards erythrocytes: Reflexion of a pathogenetic mechanism?
10. Increased plasma levels of lead in patients with amyotrophic lateral sclerosis compared with control subjects as determined by flameless atomic absorption spectrophotometry
11. Long-time penicillamine-treatment in amyotrophic lateral sclerosis with parallel determination of lead in blood, plasma and urine
12. Cadmium and selenium in blood and urine related to smoking habits and previous exposure to mercury vapour
13. Increased inorganic mercury in spinal motor neurons following chelating agents
14. Reference intervals for trace elements in blood: Significance of risk factors
15. Response to penicillamine of lead concentrations in CSF and blood in patients with motor neurone disease
16. Trace element imbalances in amyotrophic lateral sclerosis
17. Toxic trace element reference levels in blood and urine: Influence of gender and lifestyle factors
18. Overview on the protection given by selenium against mercurials
19. Lead content of cerebrospinal fluid and other tissue in amyotrophic lateral sclerosis (ALS)
20. Heavy metals and trace elements in amyotrophic lateral sclerosis
21. 2) per os
22. Mercury and selenium contents in amyotrophic lateral sclerosis in Hokkaido, the northernmost island of Japan
23. Heavy metal concentrations in blood cells in patients with amyotrophic lateral sclerosis
24. Entry of low doses of mercury vapour into the nervous system
25. Shrinkage of motor axons following systemic exposure to inorganic mercury
26. Oxidative damage to nucleic acids in motor neurons containing mercury
27. Mercury in human spinal motor neurons
28. Effects of micronutrients on metal toxicity
29. Blood cadmium concentrations in the general population of British middle-aged men
30. Increased fragility of erythrocytes from amyotrophic lateral sclerosis (ALS) patients provoked by mechanical stress
31. Further studies on the erythrocyte uptake of lead in vitro in amyotrophic lateral sclerosis (ALS) patients and controls: Abnormal erythrocyte fragility in ALS
32. Toward earlier diagnosis of amyotrophic lateral sclerosis: Revised criteria
33. Diagnosis of amyotrophic lateral sclerosis
34. Amyotrophic lateral sclerosis after accidental injection of mercury
35. Biological monitoring of exposure to cadmium, a human carcinogen, as a result of active and passive smoking
36. Metallothionein immunoreactivity is increased in the spinal cord of patients with amyotrophic lateral sclerosis
37. Increased metallothionein in the liver and kidney of patients with amyotrophic lateral sclerosis
38. Lead concentrations in blood, plasma, erythrocytes and cerebrospinal fluid in amyotrophic lateral sclerosis
39. Lead, cadmium, and selenium in the blood of patients with sporadic amyotrophic lateral sclerosis
40. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria